Clinical Trial Update: Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV) [Phase 2]

View source ↗

Summary

An update on the Phase 2 exploratory trial of ZD6126 in newly diagnosed metastatic renal cell carcinoma indicates the study is suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ZD6126 (ZD6126)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Renal Cell, Kidney Neoplasms | Phase 2 | Status: SUSPENDED